CHRISTOPHER D. GALLOWAY - 27 Jan 2022 Form 4 Insider Report for Diffusion Pharmaceuticals Inc. (CRVO)

Role
Chief Medical Officer
Signature
/s/ William R. Elder, attorney-in-fact for the Reporting Person
Issuer symbol
CRVO
Transactions as of
27 Jan 2022
Net transactions value
$0
Form type
4
Filing time
31 Jan 2022, 05:06:09 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DFFN Stock Option (Right to Buy) Award $0 +305,743 $0.000000 305,743 27 Jan 2022 Common Stock 305,743 $0.2400 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing January 31, 2022.